Rocket One Inc（RKTO）资讯与事件RKTORocket One Inc

Hoth Therapeutics Ends Phase 2a Trial of HT-001 Early

Rocket One's biotechnology subsidiary, Hoth Therapeutics, has decided to end its Phase 2a clinical trial of HT-001 early following strong interim efficacy results. Hoth is preparing to seek FDA feedback on advancing HT-001 into a potential Phase 3 clinical program. HT-001 is an investigational topical formulation of aprepitant being developed to treat dermatologic toxicities associated with epidermal growth factor receptor, or EGFR, inhibitor cancer therapies. These skin complications can cause significant discomfort, affect patients' quality of life, and lead to interruptions or modifications of cancer treatment. Hoth's decision reflects its assessment of the clinical activity observed in the interim analysis and the information needed to guide further development. Hoth intends to request FDA feedback on the proposed pathway for HT-001. Initiation of a Phase 3 trial will depend on regulatory feedback, completion of required development activities. HT-001 remains investigational and has not been approved by the FDA for any indication.

Rocket One Signs Research Agreement with Virginia Commonwealth University

Rocket One announced that it has executed a sponsored research agreement with Virginia Commonwealth University to advance SKYMRAM, a skyrmion-based magnetic memory technology with potential applications in next-generation AI chips and computing systems. The agreement establishes a one-year research program scheduled to begin November 1, 2026. The work will focus on nanoscale fabrication, materials optimization, and device-level testing toward a critical proof-of-concept milestone: demonstrating switching of SKYMRAM's soft magnetic layer. For Rocket One, the agreement establishes a defined experimental development program supporting its broader strategy to pursue advanced semiconductor technologies for AI infrastructure, space, and defense applications.

Rocket One Signs Patent License Agreement with Air Force

Rocket One has signed a patent license agreement with the Department of the Air Force covering technology designed to capture hostile drones and isolate their communications, expanding the company's counter-unmanned aircraft systems technology portfolio. The 12-month Evaluation Patent License Agreement grants Rocket One rights to evaluate the invention in the United States across applications including military-base protection, airports and airfields, homeland and border security, maritime and port security, critical infrastructure, correctional facilities, and government facilities. The patented architecture describes a friendly drone deploying a containment unit around a target unmanned vehicle, with shielding designed to interrupt communications between the target and its operator. Additional configurations described in the patent may support localized spoofing, jamming and signal-intelligence functions. The company sees potential to complement Swarm Stage AI, its drone-swarm threat-emulation and counter-UAS training platform, by evaluating a physical interception approach alongside simulated threat scenarios. The agreement provides evaluation rights only and does not authorize commercial sales. Any future commercialization would require additional rights and applicable approvals.